Business
Sandoz CEO, Speaking at 44th Annual J.P. Morgan Healthcare Conference, Will Outline Plans to Capitalize on Unprecedented Golden Decade of Affordable Medicines Opportunity
After consistently delivering on commitments in first two years as standalone company, Sandoz has unique leading position in biosimilar and generic market Strong momentum supports plans to capture significant share of unprecedented global mark...
About this update from Sandoz Group Ltd
[{"type":"table","headerItems":[],"items":[{"val":[{"val":[{"type":"list","items":[{"val":[{"type":"text","content":"After consistently delivering on commitments in first two years as standalone company, Sandoz has unique leading position in biosimilar and generic market","length":154,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":154,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Strong momentum supports plans to capture significant share of unprecedented global market opportunity, with medicines worth more than USD 600 billion due to lose exclusivity over next decade","length":191,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":191,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Sandoz committed to make next 10 years golden decade' of patient access to affordable medicines","length":99,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":99,"olType":false},{"type":"text","content":"BASEL, SWITZERLAND - January 12, 2026 (NEWMEDIAWIRE) - Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in affordable medicines, will today outline its plans to capitalize on the unprecedented market opportunity of the coming golden decade', in a presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, at 18:45 CET (9:45 PST).","length":381,"tagName":"p"},{"type":"text","content":"Speaking at the conference, taking place from January 12 to 15 in San Francisco, CEO Richard Saynor will highlight the company's strong and consistent progress in its first two years as a standalone global leader, its unique positioning and strategic focus as a pure-play' biosimilar and generic company and its determination to capitalize on an unprecedented market loss of exclusivity (LoE) opportunity over the next decade.","length":434,"tagName":"p"},{"type":"text","content":"He will say: "I'm proud that we remain consistently on track, and in some cases exceed, on the commitments we have made since becoming an independent company in 2023. As the global leader in the affordable medicines industry, which accounts for 80% of medicines used at just 30% of the total cost, we already have tremendous impact on making healthcare more accessible for all. And we stand today on the cusp of the biggest golden decade' in the history of the phar...